News

Reportedly, an earlier related patent, US patent 6890931 B2 (‘931 patent), was issued in 2005 and covers methods of treating Fragile X Syndrome with group 1 antagonists of

The company claims that the new facility is the largest Thermo Fisher Scientific center in the North of England and one of its biggest in the UK. The

Daiichi Sankyo and Ranbaxy Mexico have agreed to commercialize olmesartan medoxomil, an antihypertensive discovered by Daiichi Sankyo, in Mexico. Additionally, the companies have agreed to promote prasugrel, an

Under the terms of the agreement, the Pancreas, Biliary and Liver Surgery Center of New York will provide specimens from their collected specimen banks, as well as blood

Reportedly, the proposed transaction between the two organisations is subject to customary regulatory and closing conditions. The transaction is expected to close within the next two months. Ian

Chemizon will be responsible for a spectrum of activities for an integrated drug development program including lead optimisation, assay development, ADME, DMPK, computational chemistry and animal pharmacology. Jin

Alexza submitted its New Drug Application (NDA) for Staccato loxapine in December 2009. The company is seeking regulatory approval to market AZ-004, an inhalation product candidate developed for

The performance of the novel biomarker, AGR2, will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data, it is expected

Athersys also announced that it has been granted (the opposition period has cleared) EP patent EP1218489B1 that covers non-embryonic pluripotent stem cells, their isolation, expansion, and usage. The